27 Apr Bemetrazole 400mg Tablets (Metronidazole)
| Company name & Address: |
registration number |
Batch number(s) |
Expiry date |
Pack size |
First date of release |
Re-call Classification |
Recall date
|
| Ranbaxy Pharmaceuticals (Pty) Ltd
14 Lautre Road, Stormill Extension 1. Roodepoort, Johannesburg 1724, South Africa |
X/20.2.6/84 |
AC80212 and AC80213 |
08/2024 (both batches) |
500’s
|
26.Sep.2022 (both batches) |
Class II Type B
|
18.Aug.2023 |
Reason for recall
This recall was initiated due to discolouration of tablets.
Advice to HCPs/Distributors/Public:
The company requested their clients to refrain from selling any of the affected batches of Bemetrazole 400mg, Batch AC80212 and AC80213, and to return all remaining stock to their supplying warehouse or distributor with immediate effect. Ranbaxy Pharmaceuticals (Pty) Ltd will collect all your stock which will be credited.
Proposed action taken and its urgency: A SAHPRA approved recall letter was distributed to all distribution points and the recall process was initiated.
Reporting side effects
Public and healthcare professionals are encouraged to report any side effects after using a health product or after immunisation by using the Med Safety App. Your report will contribute to our monitoring of these health products.